These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33001991)

  • 1. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
    Bories P; Prade N; Lagarde S; Cabarrou B; Largeaud L; Plenecassagnes J; Luquet I; De Mas V; Filleron T; Cassou M; Sarry A; Fornecker LM; Simand C; Bertoli S; Recher C; Delabesse E
    PLoS One; 2020; 15(10):e0238795. PubMed ID: 33001991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
    Müller-Thomas C; Rudelius M; Rondak IC; Haferlach T; Schanz J; Huberle C; Schmidt B; Blaser R; Kremer M; Peschel C; Germing U; Platzbecker U; Götze K
    Haematologica; 2014 Oct; 99(10):e179-81. PubMed ID: 24972774
    [No Abstract]   [Full Text] [Related]  

  • 4. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
    N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
    Döhner H; Dolnik A; Tang L; Seymour JF; Minden MD; Stone RM; Del Castillo TB; Al-Ali HK; Santini V; Vyas P; Beach CL; MacBeth KJ; Skikne BS; Songer S; Tu N; Bullinger L; Dombret H
    Leukemia; 2018 Dec; 32(12):2546-2557. PubMed ID: 30275526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
    Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
    Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
    Bohl SR; Dolnik A; Jensen T; Lang KM; Hackanson B; Gaidzik VI; Paschka P; Knudsen S; Döhner K; Döhner H; Claus R; Lübbert M; Bullinger L
    Leuk Lymphoma; 2017 Sep; 58(9):1-4. PubMed ID: 28278722
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutations and azacitidine treatment: to be or not to be related?
    Rigolin GM; Cuneo A
    Leuk Res; 2014 Jul; 38(7):727-8. PubMed ID: 24836763
    [No Abstract]   [Full Text] [Related]  

  • 11. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
    Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azacitidine effectively reduces
    Takei T; Yokoyama K; Shimizu E; Konuma T; Takahashi S; Yamaguchi R; Imoto S; Miyano S; Tojo A
    Leuk Lymphoma; 2018 Nov; 59(11):2755-2756. PubMed ID: 29648492
    [No Abstract]   [Full Text] [Related]  

  • 13. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
    Ramos F; Thépot S; Pleyer L; Maurillo L; Itzykson R; Bargay J; Stauder R; Venditti A; Seegers V; Martínez-Robles V; Burgstaller S; Récher C; Debén G; Gaidano G; Gardin C; Musto P; Greil R; Sánchez-Guijo F; Fenaux P;
    Leuk Res; 2015 Mar; 39(3):296-306. PubMed ID: 25601157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
    Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
    Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
    [No Abstract]   [Full Text] [Related]  

  • 15. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
    Metzeler KH; Walker A; Geyer S; Garzon R; Klisovic RB; Bloomfield CD; Blum W; Marcucci G
    Leukemia; 2012 May; 26(5):1106-7. PubMed ID: 22124213
    [No Abstract]   [Full Text] [Related]  

  • 17. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network.
    Bories P; Bertoli S; Bérard E; Laurent J; Duchayne E; Sarry A; Delabesse E; Beyne-Rauzy O; Huguet F; Récher C
    Am J Hematol; 2014 Dec; 89(12):E244-52. PubMed ID: 25195872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 or Not TP53: That Is the Question.
    Green SD; Zeidner JF
    Clin Cancer Res; 2022 Dec; 28(24):5235-5237. PubMed ID: 36197410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.
    Maurillo L; Venditti A; Spagnoli A; Gaidano G; Ferrero D; Oliva E; Lunghi M; D'Arco AM; Levis A; Pastore D; Di Renzo N; Santagostino A; Pavone V; Buccisano F; Musto P
    Cancer; 2012 Feb; 118(4):1014-22. PubMed ID: 21761399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
    Hiller JK; Schmoor C; Gaidzik VI; Schmidt-Salzmann C; Yalcin A; Abdelkarim M; Blagitko-Dorfs N; Döhner K; Bullinger L; Duyster J; Lübbert M; Hackanson B
    Ann Hematol; 2017 Apr; 96(4):559-565. PubMed ID: 28058491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.